Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Journal of Cancer

• Publication date

  2007-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.EJCA.2007.04.023PMID 17574839
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct-to-patient BRCA1 testing: the Twoj Styl experience

  2006cited by this paper
• BRCA1-positive breast cancers in young women from Poland

  2006cited by this paper
• Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

  2005cited by this paper
• Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2005cited by this paper
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2004cited by this paper
• Ratio of female to male offspring of women tested for BRCA1 and BRCA2 mutations

  2004cited by this paper
• The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.

  2003cited by this paper
• Uptake of BRCA1 Genetic Testing in Adult Sisters and Daughters of Known Mutation Carriers in Norway

  2003cited by this paper
• Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy

  2002cited by this paper
• Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer

  2002cited by this paper
• Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

  2002cited by this paper
• The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series.

  2001cited by this paper
• Genetic epidemiology of BRCA1 mutations in Norway.

  2001cited by this paper

• BRCA awareness and testing experience in the UK Jewish population: a qualitative study

  2024cites this paper
• Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.

  2024cites this paper
• Analysis of the occurrence of germline mutations BRCA1\2, PALB2, CHEK2, NBN in patients with pancreatic malignancies. Single-center cohort non-randomized retrospective study

  2024cites this paper
• Application of Genomic Data in Translational Medicine During the Big Data Era.

  2024cites this paper
• Optimizing Ovarian Cancer Treatment and Prevention Through Parallel Germline and Somatic Genetic Testing.

  2024cites this paper
• Clinical significance of germline mutations in BRCA1/2 gene in pancreatic ductal adenocarcinoma (literature review)

  2024cites this paper
• Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada

  2024cites this paper
• Prevalence of Germline Pathogenic BRCA mutations in women with High grade Serous ovarian cancers

  2023cites this paper
• BRCA1/BRCA2-Associated Pancreatic Cancer: Case Series

  2023cites this paper
• Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies

  2022cites this paper
• A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot

  2022cites this paper
• Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting

  2022cites this paper
• Pathogenicity Reclassification of Genetic Variants Related to Early-Onset Breast Cancer among Women of Mongoloid Origin

  2022cites this paper
• Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program

  2022cites this paper
• Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations

  2022cites this paper
• Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland

  2022cites this paper
• Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis

  2021cites this paper
• BRCA mutated pancreatic cancer: A change is coming

  2021cites this paper
• Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population

  2021cites this paper
• Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa

  2021cites this paper
• Does genetic testing have any role for elderly breast cancer patients? A narrative review

  2021cites this paper
• High frequency of BRCA recurrent mutations in a consecutive series of unselected ovarian cancer patients

  2020cites this paper
• Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.

  2020cites this paper
• Population-based genetic testing for Women's cancer prevention.

  2020cites this paper
• The genetic structure of Norway

  2020cites this paper
• Peridiagnostic and cascade cancer genetic testing

  2020cites this paper
• The latest first-line treatment options for ovarian cancer: focus on maintenance therapy

  2020cites this paper
• Whole exome sequencing reveals a combination of rare high and low penetrance variants that correlates with familial breast cancer relative risk

  2020cites this paper
• СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ПЕРВОЙ ЛИНИИ ТЕРАПИИ РАКА ЯИЧНИКОВ: ФОКУС НА ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ

  2020cites this paper
• Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems

  2020cites this paper
• The contemporary landscape of genetic testing and breast cancer: Emerging issues

  2020cites this paper
• Practical aspects of treating relapsed BRCA-associated ovarian cancer

  2019cites this paper
• Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing

  2019cites this paper
• Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer

  2019cites this paper
• A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

  2019cites this paper
• Практические аспекты лечения рецидивов BRCA-ассоциированного рака яичников

  2019cites this paper
• Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation

  2019cites this paper
• Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift

  2019cites this paper
• Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a “Traceback” approach

  2018cites this paper
• Diagnostic accuracy, clinical effectiveness and budget impact of screening BRCA1/2 mutation carriers by MRI. A health technology assessment

  2018cites this paper
• BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway

  2018cites this paper
• Prevalence of Five BRCA1/2 Mutations in Bulgarian Breast Cancer Patients

  2018cites this paper
• Hereditary breast cancer in South-Eastern Norway BRCA 1 / 2-testing of breast cancer patients . Mutation spectrum and potential modifiers in Norwegian BRCA 1 / 2 carriers

  2018cites this paper
• Hereditary breast cancer in South-Eastern Norway BRCA1/2- testing of breast cancer patients. Mutation spectrum and potential modifiers in Norwegian BRCA1/2 carriers

  2018cites this paper
• Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

  2018cites this paper
• Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history

  2018cites this paper
• Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?

  2018cites this paper
• Effect of organized mammography screening on breast cancer mortality: A population‐based cohort study in Norway

  2018cites this paper
• Electronically ascertained extended pedigrees in breast cancer genetic counseling

  2018cites this paper
• High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study

  2018cites this paper
• Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds

  2018cites this paper
• Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer

  2017cites this paper
• Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers

  2017influential citation
• BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer

  2017cites this paper
• Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

  2017cites this paper
• Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer

  2017cites this paper
• Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families

  2017cites this paper
• Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance

  2017cites this paper
• Our genes, our selves: hereditary breast cancer and biological citizenship in Norway

  2017cites this paper
• Clinical Applications of Next-Generation Sequencing in Cancer Diagnosis

  2017cites this paper
• A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer

  2017cites this paper
• Assessing Women's attitudes Towards Genetic Testing For Hereditary Breast Cancer

  2017cites this paper
• Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.

  2017cites this paper
• Treatment of BRCA1/2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017influential citation
• Treatment of BRCA 1 / 2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017influential citation
• A discrete event simulation model was developed that included the risks of breast and ovarian cancer, the costs, utilities and effects of risk-reducing surgery on cancer rates, and the costs, utilities and mortality rates associated with cancer.

  2016cites this paper
• Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality

  2016cites this paper
• Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention

  2016influential citation
• Our genes, our selves: hereditary breast cancer and biological citizenship in Norway

  2016cites this paper
• Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.

  2016cites this paper
• Genetic screening for gynecological cancer: where are we heading?

  2016cites this paper
• rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility

  2016cites this paper
• A discrete event simulation to evaluate the cost effectiveness of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer

  2016cites this paper
• Ethics and genomic medicine, how to navigate decisions in surgical oncology

  2015cites this paper
• Survival is Better After Breast Conserving Therapy than Mastectomy for Early Stage Breast Cancer: A Registry-Based Follow-up Study of Norwegian Women Primary Operated Between 1998 and 2008

  2015cites this paper
• Imaging surveillance programs for women at high breast cancer risk in Europe: Are women from ethnic minority groups adequately included? (Review).

  2015cites this paper
• UK BRCA mutation testing in patients with ovarian cancer

  2015cites this paper
• Ten modifiers of BRCA1 penetrance validated in a Norwegian series

  2015cites this paper
• BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

  2015cites this paper
• BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia.

  2014cites this paper
• Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing

  2014cites this paper
• Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial

  2014influential citation
• Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2

  2014cites this paper
• The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation

  2014influential citation
• Systemic treatment for recurrent epithelial ovarian cancer

  2013cites this paper
• Identification of low-penetrance alleles, genetic modifiers and mutation analysis in familial breast cancer cases

  2013cites this paper
• Brystkreftkirurgi i Norge 1986-2009

  2013cites this paper
• Presence of brain metastases in patients with ovarian cancer: a place for BRCA1/2 gene testing?

  2013cites this paper
• Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas

  2013cites this paper
• Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.

  2013cites this paper
• The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe

  2013cites this paper
• Technical and implementation issues in using next-generation sequencing of cancers in clinical practice

  2013cites this paper
• [Breast cancer surgery in Norway 1986-2009].

  2013cites this paper
• Age‐specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway

  2013cites this paper
• Triple-negative breast cancer: molecular characterization and targeted therapies

  2013cites this paper
• How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

  2012cites this paper
• Deletion of Chromosomes 13q and 14q Is a Common Feature of Tumors with BRCA2 Mutations

  2012cites this paper
• Ovarian Cancer: Advances in First-Line Treatment Strategies with a Particular Focus on Anti-Angiogenic Agents

  2012cites this paper
• Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

  2012cites this paper
• Full-Exon Pyrosequencing Screening of BRCA Germline Mutations in Mexican Women with Inherited Breast and Ovarian Cancer

  2012cites this paper